about
Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UKIdiopathic pulmonary fibrosis: Diagnosis, epidemiology and natural historyNew perspectives on basic mechanisms in lung disease. 1. Lung injury, inflammatory mediators, and fibroblast activation in fibrosing alveolitisEpstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis.Rheumatoid arthritis-interstitial lung disease-associated mortality.Review of cryptogenic fibrosing alveolitis, including current treatment guidelinesRecent advances in the aetiology of cryptogenic fibrosing alveolitis.What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust.Adult height and cryptogenic fibrosing alveolitis: a case-control study using the UK general practice research database.Adult familial cryptogenic fibrosing alveolitis in the United KingdomDoes cryptogenic fibrosing alveolitis carry an increased risk of death from lung cancer?Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy.Accuracy of diagnostic coding of hospital admissions for cryptogenic fibrosing alveolitis.Human diseases of telomerase dysfunction: insights into tissue aging.Mortality rates from cryptogenic fibrosing alveolitis in seven countries.Accuracy of mortality data for interstitial lung diseases in New Mexico, USADiffuse lung disease: an approach to managementPulmonary fibrosis is associated with an elevated risk of thromboembolic disease.Genetic and environmental factors influencing human diseases with telomere dysfunction.Epidemiology of idiopathic pulmonary fibrosis.Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century.TGF-beta antibodies: a novel treatment for pulmonary fibrosis?The burden of lung disease.Idiopathic pulmonary fibrosis and hepatitis C virus infection.Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.Mortality from idiopathic pulmonary fibrosis: a temporal trend analysis in Brazil, 1979-2014.Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK.
P2860
Q24670477-B02A36CD-1F64-4D96-87D6-36151BCC256DQ26776473-6951EED3-E4BF-45CA-BF89-08D5EFCFCCD0Q33604630-A5F940AE-8068-4C56-898F-8AFA0E7C81C2Q33605234-A752555B-EC74-4365-8B38-C4C81FFC633EQ33744934-E5C70042-D7A9-4BC4-A7DA-D305EE95C0E0Q34048271-0C227577-4012-491A-8E6D-1636C58D6E56Q34105545-16078E7E-CF0B-4569-B1F7-163CA4DDFF65Q35170988-ACB5EF21-3360-4B27-92D4-5384E104F1E5Q35533436-27DB6FA4-0B9F-4A9C-852C-960E78C9C58EQ35533607-D8EA76D8-7433-4FDC-961E-943FB3F9C813Q35558538-5351AC64-53D3-4C6F-91D9-C8383BA646E8Q35913543-2AAB6D16-F4A9-46F2-B342-E725529F1C64Q36247676-C918AEFA-3409-4945-AAF0-05AA31179AE4Q36360681-45B71103-DBA4-4759-9DF9-070842812A44Q36496348-78368179-7986-4A7C-8C1B-A70F2C0E599BQ36496362-8177707B-0757-41E6-99CD-24E8ED3BFE13Q36886460-8A9A72C9-8F0A-4446-8EF0-BE210086821EQ37133224-6B1FAD37-33B9-4269-99B3-3937A8F4760BQ37285981-344E5F0D-B31E-4FB6-931A-038444735E8BQ37359126-646C9A67-EB1B-454A-AE77-2A53D5F0F1BCQ39138520-867FD298-9C5A-4F0C-8426-CFC9422D0B87Q42510654-8B860774-EB5F-4CB3-972D-187CA184A784Q42743927-1063F24C-6A88-4FEB-9EE0-874D063DB0E3Q43035239-3C779B6F-BAC1-4A1F-9914-52C1771753A8Q47656318-77A770F8-D248-4C7C-A8B2-8BF0BD9B164BQ48516795-1C68BC3C-0CC2-4483-880C-C9FB06B78E20Q55021008-97620FB6-DC88-4E0A-B6CE-B1F84930A213
P2860
description
1990 nî lūn-bûn
@nan
1990 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Rising mortality from cryptogenic fibrosing alveolitis.
@ast
Rising mortality from cryptogenic fibrosing alveolitis.
@en
type
label
Rising mortality from cryptogenic fibrosing alveolitis.
@ast
Rising mortality from cryptogenic fibrosing alveolitis.
@en
prefLabel
Rising mortality from cryptogenic fibrosing alveolitis.
@ast
Rising mortality from cryptogenic fibrosing alveolitis.
@en
P2093
P2860
P1433
P1476
Rising mortality from cryptogenic fibrosing alveolitis.
@en
P2093
P2860
P304
P356
10.1136/BMJ.301.6759.1017
P407
P577
1990-11-01T00:00:00Z